101
Comments
• Fenofibrate and fenofibric acid can reversibly elevate serum creatinine
• When given in combination with statin therapy can increase risk of muscle toxicity;
gemfibrozil should not be used in combination with a statin; fenofibrate or fenofibric
acid can be used in combination with statin with monitoring
• Side effects less with prescription omega-3 fatty acids compared to nonprescription
fish oil supplements
• New onset atrial fibrillation/flutter reported
• Must monitor hepatic transaminases in patients with hepatic impairment
• DHA-containing products (omega-3 acid ethyl esters) can raise LDL-C, but not apoB
• Derived from fish and purified; use with caution in patients with known
hypersensitivity to fish and/or shellfish
• Possible increased bleeding when used in combination with an antithrombotic agent
• Monitoring liver enzymes before and during treatment is necessary
• May cause and/or exacerbate insulin resistance
• Infrequently used owing to poor tolerability and lack of proven cardiovascular benefits;
tolerability improved with long-acting products and by optimizing administration
(slow titration, administering with food, predosing with aspirin or an NSAID)
• Serious muscle toxicity possible with statin use
• Use is restricted to patients with FCS
• Decreased platelet count is possible but not common
